US Generics & Biosimilars: Five Takeaways from Access! 2021
Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual…
Tagged with AAM
Dan Leonard – President & CEO, Association for…
Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM) since August 2020, outlines his key agenda priorities as head of the…
Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure…
The Long Read: Innovation, Access & Affordability in the USA
A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to…
The Value Proposition of Generics & Biosimilars in the USA
AAM President Dan Leonard highlights the findings of the association’s most recent report and re-states the value proposition of generic and…
Biosimilar Adoption in the US: Still Lagging Behind Europe
As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…
How US Generics Firms are Responding to COVID-19 Supply Chain…
AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the…
USMCA Sets a New Standard for International Trade
Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in…
Opportunities to Fix Medicare Part D
The Association for Accessible Medicines' Chip Davis outlines the ways in which the US Medicare programme needs updating in order to promote generic…
Chip Davis – President & CEO, Association for…
The AAM's Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple…
180-Day Exclusivity: The Key Ingredient in Hatch-Waxman
The AAM's Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry…
After the Prescription Is Written, Another Challenge: Abandonment
The AAM’s Chip Davis tackles the issue of abandonment within US healthcare and proposes three measures to boost competition, thereby lowering drug…
